Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

International Journal of Neuropsychopharmacology

Volumn 13, Issue 5, 2010, Pages 635-647

  Kramer, Michelle ^a   Litman, Robert ^b   Hough, David ^a   Lane, Rosanne ^a   Lim, Pilar ^a   Liu, Yanning ^a   Eerdekens, Marille ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antipsychotics; Clinical trial; Long acting injection; Schizophrenia

Indexed keywords

CHLORPROMAZINE; DIAZEPAM; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PALIPERIDONE PALMITATE; PLACEBO; RISPERIDONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; AKATHISIA; AMENORRHEA; ANXIETY; ARTICLE; ASTHENIA; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MYALGIA; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; VOMITING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953541809     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990988     Document Type: Article

References (32)

1. Allison DB, Fontaine KR, Heo M, Mentore JL, et al. (1999). The distribution of body mass index among individuals with and without schizophrenia. Journal Clinical Psychiatry 60, 215-220.
2. Andreasen NC (1995). Symptoms, signs, and diagnosis of schizophrenia. Lancet 346, 477-481.
3. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
4. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, et al. (2001). Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? Journal Clinical Psychiatry 62, 855-859.
5. Byerly M, Fisher R, Whatley K, Holland R, et al. (2005). A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133, 129-133.
6. Davidson M, Emsley R, Kramer M, Ford L, et al. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 93, 117-130. (Pubitemid 46817944)
7. Guy W (ed.) (1976). Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment for Psychopharmacology (pp. 534-537).
8. National Institute of Mental Health: Rockville, MD. Hamann GL, Egan TM, Wells BG, Grimmig JE (1990). Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. Journal Clinical Psychiatry 51, 502-504.
9. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M (in press). Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophrenia Research.
10. Hough D, Lindenmayer JP, Gopal S, Melkote R, et al. (2009). Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 1022-1031.
11. Johnson DA, Pasterski G, Ludlow JM, Street K, et al. (1983). The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 67, 339-352.
12. Kane J, Canas F, Kramer M, Ford L, et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 90, 147-161.
13. Kane JM (2003). Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal Clinical Psychiatry 64 (Suppl.), 34-40.
14. Kane JM (2007). Treatment strategies to prevent relapse and encourage remission. Journal Clinical Psychiatry 68 (Suppl.), 27-30.
15. Karlsson P, Dencker E, Mannaert E, Boom S, et al. (2006). Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophrenia Research 81 (Suppl. 1), 85-86.
16. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
17. Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal Clinical Psychiatry 64, 1308-1315.
18. Keith SJ, Kane JM, Turner M, Conley RR, et al. (2004). Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. Journal Clinical Psychiatry 65, 120-131.
19. Kramer M, Simpson G, Maciulis V, Kushner S, et al. (2007). Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Journal Clinical Psychopharmacology 27, 6-14.
20. Laughren TP (2001). The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry 16, 418-423.
21. Leucht S, Kane JM, Kissling W, Hamann J, et al. (2005). What does the PANSS mean? Schizophrenia Research 79, 231-238.
22. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994). A new five factor model of schizophrenia. Psychiatry Quarterly 65, 299-322.
23. Lindenmayer JP, Jarboe K, Bossie CA, Zhu Y, et al. (2005). Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. International Clinical Psychopharmacology 20, 213-221.
24. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal Clinical Psychiatry 58, 538-546.
25. Marder SR, Kramer M, Ford L, Eerdekens E, et al. (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 62, 1363-1370.
26. Nasrallah HA (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatrica Scandinavica 115, 260-267.
27. Pandina GJ, Lindenmayer J-P, Lull J, Lim P, Gopal S, Kusumakar V, Yuen E, Palumbo J (2009). A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with an acute exacerbation of schizophrenia. Poster presented at the American Psychiatric Association Annual Meeting, 18 May, 2009. San Diego, C.A.
28. Robinson D, Woerner MG, Alvir JM, Bilder R, et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives General Psychiatry 56, 241-247. (Pubitemid 29125132)
29. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, et al. (1992). An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). American Journal Cardiology 70, 797-801.
30. Samtani MN, Vermeulen A, Stuyckens K (2009). Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clinical Pharmacokinetics 48, 585-600.
31. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 (Suppl. 1), 11-19.
32. Wyatt RJ (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17, 325-351.